The epilepsy, the protease inhibitor and the dodecamer: progressive myoclonus epilepsy, cystatin b and a 12-mer repeat expansion

被引:14
作者
Lalioti, MD
Antonarakis, SE
Scott, HS
机构
[1] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Genet & Bioinformat Div, Parkville, Vic 3050, Australia
[2] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA
[3] Univ Geneva, Sch Med, Div Med Genet, CH-1211 Geneva, Switzerland
[4] Univ Hosp Geneva, Geneva, Switzerland
关键词
D O I
10.1159/000072857
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Progressive myoclonus epilepsy 1 (EPM 1) or Un-verricht-Lundborg disease is a human autosomal recessive neurodegenerative disorder caused by mutations in cystatin B (CSTB). The CSTB gene maps to human chromosome 21 and encodes an inhibitor of lysosomal cysteine proteases. Five point mutations have been found, two of which are seen in numerous unrelated patients. However, the main CSTB mutation in EPM1, even among patients of different ethnic origins, is an expansion of a dodecamer repeat (CCCCGCCCCGCG) in the 5' flanking area of CSTB. Most normal alleles contain either two or three repeats.. while rarer normal alleles that are highly unstable contain between 12 and 17 repeats. Mutant expanded alleles have been reported to contain between 30 and 80 copies and are also highly unstable, particularly via parental transmission. There is no apparent correlation between mutant repeat length and disease phenotype. While the repeat expansion is outside the CSTB transcriptional unit, it results in a marked decrease in CSTB expression, at least in certain cell types in vitro. Cstb homozygous knockout mice show some parallels to the phenotype of human EPM 1 including myoclonic seizures, development of ataxia and neuropathological changes associated with cell loss via apoptosis. Loss of CSTB function due to mutations is consistent with the observed neurodegenerative pathology and phenotype, but the functional link to the epileptic phenotype of EPM 1 remains largely unknown. Copyright (C) 2002 S.Karger AG, Basel.
引用
收藏
页码:213 / 223
页数:11
相关论文
共 84 条
[1]  
ABRAHAMSON M, 1987, J BIOL CHEM, V262, P9688
[2]  
ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282
[3]   Characterization of the cystatin B gene promoter harboring the dodecamer repeat expanded in progressive myoclonus epilepsy, EPM1 [J].
Alakurtti, K ;
Virtaneva, K ;
Joensuu, T ;
Palvimo, JJ ;
Lehesjoki, AE .
GENE, 2000, 242 (1-2) :65-73
[4]  
BARRETT AJ, 1981, METHOD ENZYMOL, V80, P771
[5]   PROGRESSIVE MYOCLONUS EPILEPSIES - SPECIFIC CAUSES AND DIAGNOSIS [J].
BERKOVIC, SF ;
ANDERMANN, F ;
CARPENTER, S ;
WOLFE, LS .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 315 (05) :296-305
[6]   PROGRESSIVE MYOCLONUS EPILEPSIES - CLINICAL AND NEUROPHYSIOLOGICAL DIAGNOSIS [J].
BERKOVIC, SF ;
SO, NK ;
ANDERMANN, F .
JOURNAL OF CLINICAL NEUROPHYSIOLOGY, 1991, 8 (03) :261-274
[7]  
BERKOVIC SF, 1993, EPILEPSIA, V34, pS19
[8]   G to C transversion at a splice acceptor site causes exon skipping in the cystatin B gene [J].
Bespalova, IN ;
Pranzatelli, M ;
Burmeister, M .
MUTATION RESEARCH-GENOMICS, 1997, 382 (1-2) :67-74
[9]  
Bespalova IN, 1997, AM J MED GENET, V74, P467, DOI 10.1002/(SICI)1096-8628(19970919)74:5<467::AID-AJMG1>3.0.CO
[10]  
2-L